Sagimet Biosciences Inc. - Series A · NASDAQ:SGMT
Happel David sold 64,051 Sagimet Biosciences Inc. - Series A shares (Form 4)
Traded Jul 20, 2026 · Filed Jul 22, 2026
On Jul 20, 2026, Happel David (Director, President & CEO) sold 64,051 Sagimet Biosciences Inc. - Series A shares at US$7.76 for US$497K, leaving 741,570 shares. Filed Jul 22, 2026 (Form 4).
- Sold
- 64,051 shares
- Price
- US$7.76
- Value
- US$497K
- Holding after
- 741,570 shares
- Trading plan
- No
- Role
- Director, President & CEO
The filing in full
| Date | Security | Transaction | Shares | Price | Holding after | Ownership |
|---|---|---|---|---|---|---|
| Jul 20, 2026 | Series A Common Stock | Sale | 64,051 | US$7.76 | 741,570 | Direct |
Source
Related
- Sagimet Biosciences Inc. - Series A
- Happel David
- Sagimet Biosciences Inc. - Series A shareholders
- Schedule 13G · Commodore Capital LP · Oct 7, 2026
- Form 4 · Kemble George · Aug 17, 2026
- Schedule 13G · Balyasny Asset Management L.P. · Aug 14, 2026
- Form 4 · Kemble George · Aug 12, 2026
- Schedule 13G · BlackRock, Inc. · Jul 30, 2026